Pamplona Capital Management was on the hunt for a contract research organization (CRO). After missing out on PPD, the PE firm bagged publicly traded PAREXEL for $5.2 billion.
We’ve documented the increase in biotechnology acquisitions and license deals by pharmaceutical companies in previous posts. But the impact of pharma’s move away from in-house R&D has benefited other sectors of the healthcare industry, particularly clinical research organizations (CROs). For those outside the technology side of healthcare, CROs provide outsourced research services to the pharmaceutical, […]